Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)
- Registration Number
- NCT03370913
- Lead Sponsor
- BioMarin Pharmaceutical
- Brief Summary
This Phase III clinical study will assess the impact of BMN 270 (compared to FVIII prophylaxis) on the number of bleeding episodes irrespective of exogenous FVIII replacement treatment in the efficacy evaluation period (EEP) (from Week 5 post-BMN 270 infusion (Study Day 33) or the end of FVIII prophylaxis plus the washout period (3 days for products of standard half-life or plasma-derived and 5 days for products of extended half-life), whichever is later, to last visit by the data cut-off for the 2-year analysis, hereafter referred to as "Post FVIII Prophylaxis to Last Visit"). The study will also assess the impact of BMN 270 (compared to FVIII prophylaxis) on: the number of bleeding episodes requiring exogenous FVIII treatment in "Post FVIII Prophylaxis to Last Visit", FVIII activity as measured by chromogenic sustrate assay at Week 104 following intravenous infusion of BMN 270, usage of exogenous FVIII replacement therapy in "Post FVIII Prophylaxis to Last Visit", health-related quality of life patient-reported outcomes at week 104 following intravenous infusion of BMN 270. The study will also evaluate the safety of the BMN 270.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 144
- Males ≥ 18 years of age with hemophilia A and residual FVIII levels ≤ 1 IU/dL as evidenced by medical history, at the time of signing the informed consent.
- Must have been on prophylactic FVIII replacement therapy for at least 12 months prior to study entry.
- Treated/exposed to FVIII concentrates or cryoprecipitate for a minimum of 150 exposure days (EDs).
- No previous documented history of a detectable FVIII inhibitor, and results from a Bethesda assay or Bethesda assay with Nijmegen modification of less than 0.6 Bethesda Units (BU) on 2 consecutive occasions at least one week apart within the past 12 months.
- Detectable pre-existing antibodies to the adeno-associated virus 5 (AAV5) capsid.
- Any evidence of active infection or any immunosuppressive disorder, except for HIV infection
- Any evidence of active infection or any immunosuppressive disorder, including HIV infection (effective as of Protocol Amendment 3)
- Significant liver dysfunction.
- Prior liver biopsy showing significant fibrosis.
- Evidence of any bleeding disorder not related to hemophilia A.
- Platelet count of < 100 x 10^9/L.
- Creatinine ≥ 1.5 mg/dL.
- Liver cirrhosis of any etiology as assessed by liver ultrasound.
- Chronic or active hepatitis B.
- Active Hepatitis C.
- Active malignancy, except non-melanoma skin cancer.
- History of hepatic malignancy.
- History of arterial or venous thromboembolic events.
- Known inherited or acquired thrombophilia, including conditions associated with increased thromboembolic risk, such as atrial fibrillation.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description valoctocogene roxaparvovec Open Label valoctocogene roxaparvovec Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg
- Primary Outcome Measures
Name Time Method Change From Baseline in Annualized Number of Bleeding Episodes Irrespective of Exogenous FVIII Replacement Treatment [Annualized Bleeding Rate (ABR) for All Bleeds] in EEP. Baseline to efficacy evaluation period (EEP) All bleeds comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. All bleeds are any reported bleeding events regardless of the use of FVIII or other treatments.
ABR for all bleeds= Number of bleeding episodes for all bleeds during the calculation period / total number of days during the calculation period \* 365.25.
Baseline: prior to BMN 270 infusion while receiving FVIII prophylaxis.
EEP: From Week 5 post-BMN 270 infusion (Study Day 33) or the end of FVIII prophylaxis plus the washout period (3 days for products of standard half-life or plasma-derived and 5 days for products of extended half-life), whichever is later, to last visit by the data cut-off for the 2-year analysis, hereafter referred to as "Post FVIII Prophylaxis to Last Visit").
- Secondary Outcome Measures
Name Time Method Change From Baseline in the Annualized Number of Bleeding Episodes Requiring Exogenous FVIII Replacement Therapy (ABR for Treated Bleeds) in the EEP. Baseline to EEP ABR for treated bleeds=Number of bleeding episodes for treated bleeds during the calculation period/total number of days during the calculation period \* 365.25
Bleeds that were treated with FVIII replacement therapy (recorded as "treatment for bleed") within 72 hours and were not associated with surgery or a procedure were included.
Baseline: prior to BMN 270 infusion while receiving FVIII prophylaxis.
EEP: From Week 5 post-BMN 270 infusion (Study Day 33) or the end of FVIII prophylaxis plus the washout period (3 days for products of standard half-life or plasma-derived and 5 days for products of extended half-life), whichever is later, to last visit by the data cut-off for the 2-year analysis, hereafter referred to as "Post FVIII Prophylaxis to Last Visit").Change From Baseline in Haemo-QoL-A Quality of Life: Role Functioning Domain Score, at Week 104 Baseline to Week 104 The change from baseline (assuming no treatment for severe hemophilia A) in Haemo-Qol-A score, at week 104 post-BMN 270 infusion. The Haemo-Qol-A questionnaire is a fit for purpose hemophilia-specific health related quality of life (HRQoL) questionnaire for adults consisting of 41 items covering six domains (Physical Functioning, Role Functioning, Worry, Consequences of Bleeding, Emotional Impact and Treatment Concerns).The Haemo-Qol-A items are answered on a 6-point Likert scale ranging from 0 (none of the time) to 5 (all of the time). The recall period for the Haemo-Qol-A is one month (4-weeks).
The Haemo-Qol-A role functioning domain score is an average of each item value within a domain. The range of domain scores is 0 to 5; higher scores mean better HRQoL or less impairment for the domain. The role functioning domain score is transformed to a 0 (minimum) to 100 (maximum) scale with higher scores indicating a better or less impaired haemophilia-related role functioning.Change From Baseline in Haemo-QoL-A Quality of Life: Physical Functioning Domain Score, at Week 104 Baseline to Week 104 The change from baseline (assuming no treatment for severe hemophilia A) in Haemo-Qol-A score, at week 104 post-BMN 270 infusion. The Haemo-Qol-A questionnaire is a fit for purpose hemophilia-specific health related quality of life (HRQoL) questionnaire for adults consisting of 41 items covering six domains (Physical Functioning, Role Functioning, Worry, Consequences of Bleeding, Emotional Impact and Treatment Concerns).The Haemo-Qol-A items are answered on a 6-point Likert scale ranging from 0 (none of the time) to 5 (all of the time).The recall period for the Haemo-Qol-A is one month (4-weeks).
The Haemo-Qol-A physical functioning domain score is an average of each item value within a domain.The range of domain scores is 0 to 5; higher scores mean better HRQoL or less impairment for the domain. The physical functioning domain score is transformed to a 0 (minimum) to 100 (maximum) scale with higher scores indicating a better or less impaired haemophilia-related physical functioningChange From Baseline in FVIII Activity at Week 104 Baseline to Week 104 The change from baseline (assuming no treatment for severe hemophilia A) in FVIII activity, as measured by chromogenic substrate assay, at Weeks 104 post-BMN 270 infusion.
Each subject's FVIII activity level at Week 104 is defined as the median of the values obtained at Week 104 with the analysis window defined. The baseline value is imputed as 1 IU/dL for each subject.
Note: One of the subject's wk104 duplicate data issue was corrected in the 3 year analysis per which the mean (standard deviation) values are reported in outcome measure table.
Baseline: prior to BMN 270 infusion while receiving FVIII prophylaxis.Change From Baseline in Haemo-QoL-A Quality of Life: Total Score at Week 104 Baseline to Week 104 The change from baseline(assuming no treatment for severe hemophilia A) in Haemo-Qol-A score, at wk104 post-BMN 270 infusion.The Haemo-Qol-A questionnaire is a fit for purpose hemophilia-specific health related quality of life(HRQoL)questionnaire for adults consisting of 41 items covering 6 domains(Physical Functioning,Role Functioning,Worry,Consequences of Bleeding,Emotional Impact \&Treatment Concerns). The Haemo-Qol-A items are answered on a 6-point Likert scale ranging from 0(none of the time)to 5 (all of the time).The recall period for the Haemo-Qol-A is one month (4-weeks).
The Haemo-QoL-A domain(physical functioning, role functioning, worry, consequences of bleeding, emotional impact, treatment concern) scores range from 0 to 5 and the total score is derived by summing each domain score (range, 0 to 30). Domain and total scores are transformed to a 0 (minimum) to 100 (maximum) scale with higher scores indicating a better or less impaired haemophilia related quality of life.Change From Baseline in Annualized FVIII Utilization in EEP. Baseline to EEP The change from baseline in the annualized utilization (IU/kg/year) of exogenous FVIII replacement therapy in the Post FVIII Prophylaxis to Last Visit in the EEP.
The annualized utilization (IU/kg/year) of exogenous FVIII replacement therapy is defined as Sum of FVIII use (IU/kg) during calculation period/Total number of days during the calculation period ×365.25.
Baseline: prior to BMN 270 infusion while receiving FVIII prophylaxis.
EEP: From Week 5 post-BMN 270 infusion (Study Day 33) or the end of FVIII prophylaxis plus the washout period (3 days for products of standard half-life or plasma-derived and 5 days for products of extended half-life), whichever is later, to last visit by the data cut-off for the 2-year analysis, hereafter referred to as "Post FVIII Prophylaxis to Last Visit").Change From Baseline in Haemo-QoL-A Quality of Life: Consequences of Bleeding Domain Score, at Week 104 Baseline to Week 104 The change from baseline(assuming no treatment for severe hemophilia A)in Haemo-Qol-A score, at week 104 post-BMN 270 infusion. The Haemo-Qol-A questionnaire is a fit for purpose hemophilia-specific health related quality of life(HRQoL)questionnaire for adults consisting of 41 items covering 6 domains(Physical Functioning,Role Functioning,Worry,Consequences of Bleeding,Emotional Impact and Treatment Concerns). The Haemo-Qol-A items are answered on a 6-point Likert scale ranging from 0(none of the time) to 5(all of the time). The recall period for the Haemo-Qol-A is one month (4-wks).
The Haemo-Qol-A consequences of bleeding domain score is an average of each item value within a domain. The range of domain scores is 0 to 5; higher scores mean better HRQoL or less impairment for the domain. The consequences of bleeding domain score is transformed to a 0 (minimum) to 100 (maximum) scale with higher scores indicating a better or less impaired haemophilia-related consequences of bleeding
Trial Locations
- Locations (49)
Addenbrookes Hospital
🇬🇧Cambridge, United Kingdom
Los Angeles Orthopedic Hospital, Orthopedic Hemophilia Treatment Center
🇺🇸Los Angeles, California, United States
UC Davis Hemophilia Treatment Center
🇺🇸Sacramento, California, United States
University of California San Diego, Hematology and Oncology, Hemophilia &Thrombosis Treatment Center
🇺🇸San Diego, California, United States
UCSF Medical Center
🇺🇸San Francisco, California, United States
University of Colorado
🇺🇸Aurora, Colorado, United States
St. Joseph's Children's Hospital, Center for Bleeding and Clotting Disorders
🇺🇸Tampa, Florida, United States
Ann & Robert H. Lurie Children's Hospital of Chicago, Department of Hematology
🇺🇸Chicago, Illinois, United States
James Graham Brown Cancer Center
🇺🇸Louisville, Kentucky, United States
Tulane University Hematology & Medical Oncology
🇺🇸New Orleans, Louisiana, United States
University of Michigan, Pediatric Hematology and Oncology
🇺🇸Ann Arbor, Michigan, United States
Wayne State University, Detroit Medical Center
🇺🇸Detroit, Michigan, United States
University of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Washington University School of Medicine, Department of Pediatrics, Division of Hematology/Oncology
🇺🇸Saint Louis, Missouri, United States
UNC Hemophilia and Thrombosis Center
🇺🇸Chapel Hill, North Carolina, United States
Nationwide Children's Hospital
🇺🇸Columbus, Ohio, United States
The Royal Adelaide Hospital (RAH)
🇦🇺Adelaide, Australia
Royal Brisbane and Women's Hospital
🇦🇺Brisbane, Australia
Alfred Hospital
🇦🇺Melbourne, Australia
Fiona Stanley Hospital
🇦🇺Perth, Australia
Royal Prince Alfred Hospital
🇦🇺Sydney, Australia
University Hospital Leuven
🇧🇪Leuven, Belgium
Campinas Estadual University (UNICAMP) / Campinas Hemocentro / Hematologia E Hemoterapia Center
🇧🇷Campinas, Brazil
Parana's Hematology And Hemotherapy Center (HEMEPAR)
🇧🇷Curitiba, Brazil
Arthur De Siqueira Cavalcanti Hematology State Institute
🇧🇷Rio De Janeiro, Brazil
Sao Paulo University Clinical Hospital
🇧🇷São Paulo, Brazil
Holy Spirit Hematology and Hemotherapy Center
🇧🇷Vitória, Brazil
Regional University Hospital of Lille (CHRU de Lille)
🇫🇷Lille, France
Hopital de la Timone Marseille - Assistance Publique des Hopitaux de Marseille
🇫🇷Marseille, France
Vivantes Clinic im Friedrichshain- Landsberger Allee
🇩🇪Berlin, Germany
University Clinic Bonn
🇩🇪Bonn, Germany
Chaim Sheba Medical Center
🇮🇱Ramat Gan, Israel
Maggiore Polyclinic Hospital, IRCCS Ca' Granda, Center for Hemophilia and Thrombosis Angelo Bianchi Bonomi
🇮🇹Milan, Italy
Department of Pediatrics, Kyung Hee University Hospital at Gangdong
🇰🇷Seoul, Korea, Republic of
Charlotte Maxeke Johannesburg Academic Hospital, Hemophilia Comprehensive Care Center
🇿🇦Johannesburg, South Africa
Hospital Teresa Herrera
🇪🇸A Coruna, Spain
University Hospital Virgen del Rocio (HUVR)
🇪🇸Seville, Spain
Changhua Christian Hospital
🇨🇳Changhua, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Tri-Service General Hospital
🇨🇳Taipei, Taiwan
Glasgow Royal Infirmary, Department of Hematology
🇬🇧Glasgow, United Kingdom
St Thomas' Hospital
🇬🇧London, United Kingdom
Queen Elizabeth Hospital
🇬🇧Birmingham, United Kingdom
Barts and The London School of Medicine and Dentistry, Haemophilia Centre
🇬🇧London, United Kingdom
Hammersmith
🇬🇧London, United Kingdom
Churchill Hospital, Oxford Hemophilia and Thrombosis Center
🇬🇧Oxford, United Kingdom
University Hospital Southampton NHS Foundation Trust
🇬🇧Southampton, United Kingdom